Shares of Arcturus Therapeutics Holdings Inc. (ARCT) have lost approximately 78% from their 52-week high of $45, recorded last June, and now trade around $9.70.
This commercial mRNA medicines and vaccines company has several key catalysts lined up this quarter that could reshape the narrative - most notably, those related to ARCT-032, ARCT-810, and Kostaive.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com